Non-Hodgkin's Lymphoma News

• ESMO 2018Gender Differences in Chemo Side Effects Although outcomes and rates overall toxicity of esophagogastric cancer chemotherapy are similar for men and women, rates of nausea, diarrhea, and hair loss are higher in women, warn UK scientists.
  Medscape Medical News, October 2018
• No Chemo; Rituximab Alone for Indolent Lymphoma? New results showing a 10-year overall survival rate of 73% with rituximab alone suggest that patients can skip chemotherapy. But this may not be appropriate for all patients, suggests an expert.
  Medscape Medical News, October 2018
• 'Unexpected': Age 35 Key to Ovarian Function After Chemo for HL Age impacts recovery of ovarian function after chemotherapy for Hodgkin's lymphoma, even when regimens considered less toxic are used.
  Medscape Medical News, October 2018
• Rare Manufacturing Glitch Raises Concern Over CAR-T Therapies: Study A single leukemia cell inadvertently got mixed in with a batch of a patient's immune cells that were being manufactured into a CAR-T cell therapy and it acquired resistance to the treatment with deadly results, University of Pennsylvania researchers reported on Monday.
  Reuters Health Information, October 2018
• Risk of Second Primary Cancer on the Rise in People With HIV
  Reuters Health Information, September 2018
• Europe OKs Brigatinib for ALK+NSCLC, Other Products A positive opinion was granted for brigatinib, as well as mogamulizumab, a generic version of paclitaxel, and three new biosimilar pegfilgrastim products.
  Medscape Medical News, September 2018
• 'Watchful Waiting' for Early Follicular Lymphoma Questioned Regarding the management of early follicular lymphoma, an editorial examines the available options and asks why watchful waiting should be an option when it is not curative.
  Medscape Medical News, September 2018
• EADV 2018Alopecia Areata Trial Results, Skin Oncology Top EADV Agenda Early results from a trial of JAK inhibitors for hair loss will be unveiled at the upcoming dermatology meeting. Specialists will also delve into the adverse skin effects of immunotherapy.
  Medscape Medical News, August 2018
• First CAR T Cells Approved in Europe The European Commission has approved the first CAR T-cell product, tisagenlecleucel, for the treatment of certain leukemias and lymphomas.
  International Approvals, August 2018
• Childhood Cancer on the Rise in Europe
  Reuters Health Information, August 2018
• Routine Lab Testing of Little Value in Surveillance of Aggressive Lymphoma Routine laboratory testing has limited value in the surveillance of aggressive lymphoma in asymptomatic patients in complete remission, researchers from Australia report.
  Reuters Health Information, August 2018
• First Trial Alleging Monsanto's Roundup Causes Cancer Goes to Jury A trial in which a school groundskeeper alleged that his use of Monsanto's Roundup weed killer caused his terminal cancer will go to a California jury after lawyers for both sides delivered their closing arguments on Tuesday.
  Reuters Health Information, August 2018
• Cancer Care for Adolescents Costs More in Pediatric Institutions Costs of cancer care for adolescents are significantly higher in pediatric institutions than in adult institutions, researchers from Canada report.
  Reuters Health Information, July 2018
• Combo of RT and Chemoimmunotherapy: Best for Early FL? For early follicular lymphoma, a randomized study finds that the combination of radiation therapy and chemoimmunotherapy works better than radiotherapy alone. Will this change practice?
  Medscape Medical News, July 2018
• Lower Risk Of Follicular Lymphoma Transformation With Rituximab The risk of transformation of follicular lymphoma is significantly lower with rituximab treatment, according to results from the Aristotle study.
  Reuters Health Information, July 2018
• U.S. Judge Allows Lawsuits Over Monsanto's Roundup to Proceed to Trial A federal U.S. judge on Tuesday allowed hundreds of lawsuits alleging that Monsanto Co's glyphosate-containing weed-killer Roundup causes cancer to proceed to trial, finding that there was sufficient evidence for a jury to hear the cases.
  Reuters Health Information, July 2018
• CTI Biopharma's Cancer Drug Fails Late-Stage Trial, Shares Tumble
  Reuters Health Information, July 2018
• EHA 2018First-in-Class Drug Against CD79b Improves Survival in DLBCL The first-in-class antibody-drug conjugate polatuzumab vedotin significantly improved response and overall survival in relapsed or refractory diffuse large B-cell lymphoma.
  Medscape Medical News, June 2018
• EHA 2018Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma A novel chemotherapy-free regimen containing lenalidomide and rituximab showed similar efficacy but less toxicity than the standard combination of rituximab and chemotherapy in the RELEVANCE trial.
  Medscape Medical News, June 2018
• JAK1/2 Inhibitors Linked to Lymphoma Risk in Myelofibrosis New data show that the use of JAK1/2 inhibitors, the only FDA-approved therapies for myeloproliferative neoplasms, is associated with a risk for lymphoma.
  Medscape Medical News, June 2018